对温琴扎·孔泰杜卡、克里斯蒂安·洛利和乌戈·德·乔治给编辑的信的回复，信的主题为：帕斯夸莱·雷西格诺、大卫·洛伦特、迪莱塔·比安基尼等人的《醋酸阿比特龙治疗4周后前列腺特异性抗原下降与转移性去势抵抗性前列腺癌患者的总生存期》。《欧洲泌尿外科杂志》2016年；70卷：724 - 31页 - Suppr

Suppr

超能文献

Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.

作者信息

Rescigno Pasquale, de Bono Johann S

机构信息

The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.

出版信息

Eur Urol. 2016 Dec;70(6):e170-e171. doi: 10.1016/j.eururo.2016.05.029. Epub 2016 May 27.

DOI:10.1016/j.eururo.2016.05.029

PMID:27240941

Abstract

摘要

相似文献

Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.对温琴扎·孔泰杜卡、克里斯蒂安·洛利和乌戈·德·乔治给编辑的信的回复，信的主题为：帕斯夸莱·雷西格诺、大卫·洛伦特、迪莱塔·比安基尼等人的《醋酸阿比特龙治疗4周后前列腺特异性抗原下降与转移性去势抵抗性前列腺癌患者的总生存期》。《欧洲泌尿外科杂志》2016年；70卷：724 - 31页

Eur Urol. 2016 Dec;70(6):e170-e171. doi: 10.1016/j.eururo.2016.05.029. Epub 2016 May 27.

Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.回复：帕斯夸莱·雷西格诺、大卫·洛伦特、迪莱塔·比安基尼等。醋酸阿比特龙治疗4周后前列腺特异性抗原下降情况及转移性去势抵抗性前列腺癌患者的总生存期。《欧洲泌尿外科杂志》2016年；70卷：724 - 31页

Eur Urol. 2016 Dec;70(6):e168-e169. doi: 10.1016/j.eururo.2016.05.028. Epub 2016 May 30.

Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.对温琴察·孔泰杜卡、乔吉娅·古廖利和乌戈·德·乔治致编辑的信的回复，信的主题为：尼文·梅赫拉、大卫·多林、塞米尼·苏马纳苏里亚等人。两项III期试验（FIRSTANA和PROSELICA）中转移性去势抵抗性前列腺癌患者血浆游离DNA浓度与紫杉烷治疗结果。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2018.02.013 。

Eur Urol. 2018 Sep;74(3):e69-e70. doi: 10.1016/j.eururo.2018.05.016. Epub 2018 Jun 1.

Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.回复：醋酸阿比特龙治疗4周后前列腺特异性抗原下降情况及转移性去势抵抗性前列腺癌患者的总生存期

J Urol. 2016 Jul;196(1):103. doi: 10.1016/j.juro.2016.04.040. Epub 2016 Apr 14.

Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.

Eur Urol. 2015 Dec;68(6):e132-3. doi: 10.1016/j.eururo.2015.08.018. Epub 2015 Aug 28.

Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.对吉安多梅尼科·罗维耶洛、达尼埃莱·热纳拉利和罗伯托·彼得廖利致编辑的信的回复，信的主题为：约翰·S·德博诺、马修·R·史密斯、弗雷德·萨德等人。醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者后的后续化疗及治疗模式：COU - AA - 302的事后分析。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.06.033 。

Eur Urol. 2017 Feb;71(2):e56. doi: 10.1016/j.eururo.2016.08.011. Epub 2016 Aug 17.

Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.对罗伯特·J·范·索斯特和罗纳德·德·威特致编辑的信的回复，信的主题为：约翰·S·德博诺、马修·R·史密斯、弗雷德·萨德等人。醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者后的后续化疗及治疗模式：COU - AA - 302的事后分析。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.06.033 。

Eur Urol. 2017 Jan;71(1):e11. doi: 10.1016/j.eururo.2016.10.005. Epub 2016 Oct 14.

Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".关于《转移性去势抵抗性前列腺癌患者阿比特龙暴露与前列腺特异性抗原动力学之间的关系建模》的评论

Clin Pharmacokinet. 2017 Feb;56(2):211-212. doi: 10.1007/s40262-016-0468-2.

Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.回复：奥拉齐奥·卡福、乌戈·德·乔治、露西亚·弗拉蒂诺等。多西他赛及其他二线治疗失败后作为三线或四线治疗的去势抵抗性前列腺癌治疗的临床结果：一项意大利多中心研究的结果。《欧洲泌尿外科杂志》2015年；68卷：147 - 153页

Eur Urol. 2015 Dec;68(6):e129-31. doi: 10.1016/j.eururo.2015.08.017. Epub 2015 Aug 28.

Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.回复乌戈·德·乔治、温琴扎·孔泰杜卡和埃玛努埃拉·斯卡尔皮致编辑的信：关于马尔齐亚·德尔雷、伊丽莎·比亚斯科、斯特凡尼亚·克鲁奇塔等人的研究“血浆来源外泌体RNA中雄激素受体剪接变体7的检测强烈预测转移性前列腺癌患者对激素治疗的耐药性”。《欧洲泌尿外科杂志》2017年；71卷：680 - 7页

Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验